Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Therapeutics (Nasdaq: LYRA) announced upcoming presentations of study results for its chronic rhinosinusitis (CRS) treatments at two major medical conferences. The company will present:
1. Results from the Phase 3 ENLIGHTEN 1 study for LYR-210 at the 70th Annual Meeting of the American Rhinologic Society (ARS) on September 27-28 in Miami.
2. Additional results from the Phase 2 BEACON study for LYR-220 at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) on September 28 - October 1 in Miami.
The LYR-210 presentation will be a poster session on September 27th, while the LYR-220 presentation will be an oral presentation on September 29th, focusing on improvements in smell and sleep for CRS patients.
Lyra Therapeutics (Nasdaq: LYRA) ha annunciato prossime presentazioni dei risultati degli studi per i suoi trattamenti per la rinite cronica (CRS) in due importanti conferenze mediche. L'azienda presenterà:
1. Risultati dello studio di Fase 3 ENLIGHTEN 1 per LYR-210 durante il 70° Congresso Annuale della American Rhinologic Society (ARS) il 27-28 settembre a Miami.
2. Risultati aggiuntivi dello studio di Fase 2 BEACON per LYR-220 durante il Congresso Annuale dell'American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) dal 28 settembre al 1 ottobre a Miami.
La presentazione di LYR-210 sarà una sessione poster il 27 settembre, mentre la presentazione di LYR-220 sarà un intervento orale il 29 settembre, con un focus sui miglioramenti dell'olfatto e del sonno per i pazienti affetti da CRS.
Lyra Therapeutics (Nasdaq: LYRA) anunció próximas presentaciones de resultados de estudios para sus tratamientos de rinoconitis crónica (CRS) en dos importantes conferencias médicas. La compañía presentará:
1. Resultados del estudio de Fase 3 ENLIGHTEN 1 para LYR-210 en la 70ª Reunión Anual de la American Rhinologic Society (ARS) el 27 y 28 de septiembre en Miami.
2. Resultados adicionales del estudio de Fase 2 BEACON para LYR-220 en la Reunión Anual de la American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) del 28 de septiembre al 1 de octubre en Miami.
La presentación de LYR-210 será una sesión de póster el 27 de septiembre, mientras que la presentación de LYR-220 será una exposición oral el 29 de septiembre, centrada en las mejoras del olfato y el sueño para los pacientes con CRS.
라이라 테라퓨틱스 (Nasdaq: LYRA)는 만성 비염 (CRS) 치료에 대한 연구 결과를 두 개의 주요 의학 회의에서 발표할 예정이라고 발표했습니다. 이 회사는 다음을 발표합니다:
1. 9월 27-28일 마이애미에서 열리는 미국 비인두학회(ARS) 제70회 연례 회의에서 LYR-210에 대한 3상 ENLIGHTEN 1 연구 결과를 발표합니다.
2. 9월 28일부터 10월 1일까지 마이애미에서 열리는 미국 이비인후과–두경부 외과 학회(AAO-HNS) 연례 회의에서 LYR-220에 대한 2상 BEACON 연구의 추가 결과를 발표합니다.
LYR-210의 발표는 9월 27일 포스터 세션으로 진행될 예정이며, LYR-220의 발표는 9월 29일 진행될 구두 발표로, CRS 환자들의 후각 및 수면 개선에 초점을 맞출 것입니다.
Lyra Therapeutics (Nasdaq: LYRA) a annoncé des présentations à venir des résultats d'études pour ses traitements de rhininosinusite chronique (CRS) lors de deux grandes conférences médicales. L'entreprise présentera :
1. Les résultats de l'
2. Des résultats supplémentaires de l'
La présentation de LYR-210 sera une session d'affiches le 27 septembre, tandis que la présentation de LYR-220 sera une présentation orale le 29 septembre, axée sur les améliorations de l'odorat et du sommeil des patients CRS.
Lyra Therapeutics (Nasdaq: LYRA) gab die bevorstehenden Präsentationen von Studienergebnissen zu seinen chronischen Rhinosinusitis (CRS)-Behandlungen auf zwei großen medizinischen Konferenzen bekannt. Das Unternehmen wird Folgendes präsentieren:
1. Ergebnisse der Phase 3 ENLIGHTEN 1 Studie für LYR-210 auf dem 70. Jahreskongress der American Rhinologic Society (ARS) am 27.-28. September in Miami.
2. Zusätzliche Ergebnisse der Phase 2 BEACON Studie für LYR-220 auf dem Jahreskongress der American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) vom 28. September bis 1. Oktober in Miami.
Die Präsentation von LYR-210 wird am 27. September in Form eines Posterbeitrags stattfinden, während die Präsentation von LYR-220 am 29. September als mündliche Präsentation stattfinden wird, mit dem Fokus auf Verbesserungen des Geruchs- und Schlafsinns bei CRS-Patienten.
- None.
- None.
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company’s lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The Company will also present additional results from the Phase 2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), taking place September 28 - October 1 in Miami.
A poster presentation on LYR-210 will be featured at the ARS Annual Meeting and an oral presentation on LYR-220 will be featured at the AAO-HNS Annual Meeting.
Presentation Details:
Poster Presentation
American Rhinologic Society (ARS) 2024 Annual Meeting
Title: Efficacy and safety of LYR-210 for CRS from the pivotal Phase 3 ENLIGHTEN 1 trial
Presenting Author: Vineeta Belanger, PhD, Lyra Therapeutics
Date and Time: Poster Session, Friday, September 27th at 1:00-8:00 p.m. ET
Scientific Oral Presentation
American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) 2024 Annual Meeting
Title: LYR-220 24-Week Steroid-Eluting Sinus Insert Improves Smell and Sleep in Patients with Chronic Rhinosinusitis
Presenting Author: Zachary M. Soler, MD, MSc, Medical University of South Carolina, Charleston, SC
Date and Time: Sunday, September 29th at 1:06 p.m. ET
Session: Rhinology/Allergy (1:00 – 2:00 p.m. ET)
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS). Lyra Therapeutics is developing therapies for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210, the company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy (7500µg mometasone furoate) to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase 3 clinical program, is intended for patients with standard anatomy, primarily patients who have not undergone ethmoid sinus surgery. The company’s therapies are intended to treat the estimated four million CRS patients in the United States who fail medical management each year. For more information, please visit www.lyratx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the date, time and details of the presentations at ARS and AAO-HNS. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors discussed under the caption "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact Information:
Jason Cavalier, Chief Financial Officer
917.584.7668
jcavalier@lyratx.com
Media Contact:
Kathryn Morris, The Yates Network LLC
914.204.6412
kathryn@theyatesnetwork.com
FAQ
What studies will Lyra Therapeutics present at the ARS and AAO-HNS meetings in September 2024?
When and where will Lyra Therapeutics (LYRA) present its LYR-210 study results?
What is the focus of Lyra Therapeutics' (LYRA) LYR-220 presentation at the AAO-HNS meeting?
Who will present Lyra Therapeutics' (LYRA) LYR-220 study results at the AAO-HNS 2024 Annual Meeting?
